Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Transplant Cell Ther. 2021 Feb 4;27(5):389.e1–389.e10. doi: 10.1016/j.jtct.2021.02.002

Figure 3. Cytostatic effects of IFNy on MSCs are reversed by Ruxolitinib treatment.

Figure 3.

MSCs (3000 cells/ well) were seeded in 96 well plate and treated with IFNγ (20 ng/mL) and/or different concentrations of Ruxolitinib for up to 5 days. MTT dye was added 5 hours prior to measuring optical density at 550 nm with 620 nm as reference in a plate reader. Observations were made at the same time each day for 5 days. (A) The effect of different concentrations of Ruxolitinib over 5-day period is shown. (B) Day 5 data is shown in a bar graph format to specific impact of different Ruxolitinib concentration. Data shown are means ±SD of three independent experiments. Two-Way ANOVA multiple comparison test was performed between IFNγ and IFNγ +Ruxolitinib. **, ***, **** represents P ≤ 0.01, P ≤ 0.001 and P ≤ 0.0001 respectively.